Potent and selective histamine H3 receptor antagonist (pKi values are 7.61 and 8.27 at rat and human H3 receptors respectively). A steroidal alkaloid that displays in vitro antiplasmodial activity (IC50 = 1.04 μM). Also has high affinity for α2C adrenoceptors (pKi = 7.98).
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|DMSO||17.85||50mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 356.59. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.8 mL||14.02 mL||28.04 mL|
|5 mM||0.56 mL||2.8 mL||5.61 mL|
|10 mM||0.28 mL||1.4 mL||2.8 mL|
|50 mM||0.06 mL||0.28 mL||0.56 mL|
References are publications that support the products' biological activity.
Zirihi et al (2005) Isolation, characterization and antiplasmodial activity of steroidal alkaloids from Funtumia elastica (Preuss) Stapf. Bioorg.Med.Chem.Lett. 15 2637 PMID: 15863333
Zhao et al (2008) The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. J.Med.Chem. 51 5423 PMID: 18683917
If you know of a relevant reference for Conessine, please let us know.
View Related Products by Product Action
Keywords: Conessine, supplier, Potent, selective, H3, receptor, antagonists, Receptors, Histamine, histaminergic, Histamine, H3, Receptors, Histamine, H3, Receptors, Tocris Bioscience
Citations for Conessine
Citations are publications that use Tocris products.
Currently there are no citations for Conessine. Do you know of a great paper that uses Conessine from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.